Summary of Clinical Use

Trebananib is being evaluated in Phase 3 trials (using its research code AMG 386) as a potential treatment for ovarian cancer (including fallopian tube cancer and primary peritoneal cancer). In 2014 the first set of Phase 3 results were published [4] (from the TRINOVA-1 trial). The results of additional Phase 3 trials are pending (TRINOVA-2 and -3). Many other clinical trials, at various stages of development, evaluating trebananib in combination with chemotherapy are underway in a variety of solid tumors, including breast, colorectal, gastric and renal cell cancers. Click here to link to ClinicalTrials.gov's compete listing of current AMG 386 trials.

Mechanism Of Action and Pharmacodynamic Effects

Trebananib inhibits the interaction between the Tie2 receptor and the growth factors angiopoietin-1 and angiopoietin-2 (ang1 and ang2). Synthetic peptide sequences within the construct bind to ang1 and ang2 [1]. These angiopoetins promote the development of new blood vessels and lymph ducts. Inhibition of the effects of ang1 and ang2 would be expected to limit tumour survival by decreasing the formation of the new vessels required for blood supply.